Literature DB >> 3106279

Characterization of three monoclonal antibodies (VAK3-5) that identify p24, core protein of human immunodeficiency virus, and its precursors.

T Hattori, K Sagawa, S Matsushita, A Koito, H Suto, M Matsuoka, M Yokoyama, K Takatsuki.   

Abstract

VAK3, VAK4 and VAK5 monoclonal antibodies (mAbs) were raised by using disrupted purified human immunodeficiency virus (HIV) as an antigen. These mAbs exclusively reacted with an HIV-infected cell line, H9/HIV, and did not react with human T cell lymphotropic virus (HTLV)-I or -II infected cell lines. Strip radioimmunoassay based on the Western blotting technique revealed that these mAbs recognize a single band that corresponds to a 24-kd (p24) core protein of HIV when disrupted viruses were used as antigens. When cell lysates of H9/HIV were used as antigens, these mAbs gave two bands with molecular weights of 40 kd (p40) and 57 kd (p57) in addition to p24. VAK5-conjugated Sepharose 4B beads precipitated non-glycosylated proteins, p24, p40 and p57 from [L-35S]methionine-labeled H9/HIV. P57 and p40 appear to be a precursor and an intermediate precursor of p24, respectively. Purified IgG of VAK3 and VAK4, and the serum from an individual infected with HIV inhibited the binding of VAK5 mAb to HIV. These findings suggest that p24 of HIV contains structure(s) with strong antigenicity.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3106279

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  8 in total

1.  An African green monkey lacking peripheral CD4 lymphocytes that retains helper T cell activity and coexists with SIVagm.

Authors:  Y Murayama; R Mukai; M Inoue-Murayama; Y Yoshikawa
Journal:  Clin Exp Immunol       Date:  1999-09       Impact factor: 4.330

2.  Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor.

Authors:  M A el-Farrash; M J Kuroda; T Kitazaki; T Masuda; K Kato; M Hatanaka; S Harada
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

3.  Use of a human immunodeficiency virus type 1 Rev mutant without nucleolar dysfunction as a candidate for potential AIDS therapy.

Authors:  R A Furuta; S Kubota; M Maki; Y Miyazaki; T Hattori; M Hatanaka
Journal:  J Virol       Date:  1995-03       Impact factor: 5.103

4.  Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope.

Authors:  S Matsushita; M Robert-Guroff; J Rusche; A Koito; T Hattori; H Hoshino; K Javaherian; K Takatsuki; S Putney
Journal:  J Virol       Date:  1988-06       Impact factor: 5.103

5.  Expression of Ley antigen in human immunodeficiency virus-infected human T cell lines and in peripheral lymphocytes of patients with acquired immune deficiency syndrome (AIDS) and AIDS-related complex (ARC).

Authors:  M Adachi; M Hayami; N Kashiwagi; T Mizuta; Y Ohta; M J Gill; D S Matheson; T Tamaoki; C Shiozawa; S Hakomori
Journal:  J Exp Med       Date:  1988-02-01       Impact factor: 14.307

6.  Critical amino acids within the human immunodeficiency virus type 1 envelope glycoprotein V4 N- and C-terminals contribute to virus entry.

Authors:  Yan Li; Dan Yang; Jia-Ye Wang; Yuan Yao; Wei-Zhe Zhang; Lu-Jing Wang; De-Chun Cheng; Feng-Kun Yang; Feng-Min Zhang; Min Zhuang; Hong Ling
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

7.  Inhibition of human immunodeficiency virus infection of human lymphocytes by gangliosides.

Authors:  H Nakakuma; T Kawaguchi; A Koito; T Hattori; T Kagimoto; K Takatsuki
Journal:  Jpn J Cancer Res       Date:  1989-08

8.  Mutations of Glu560 within HIV-1 Envelope Glycoprotein N-terminal heptad repeat region contribute to resistance to peptide inhibitors of virus entry.

Authors:  Chen Yuan; Jia-Ye Wang; Hai-Jiao Zhao; Yan Li; Di Li; Hong Ling; Min Zhuang
Journal:  Retrovirology       Date:  2019-12-03       Impact factor: 4.602

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.